Affiliation:
1. College of Animal Science and Technology Northeast Agricultural University Harbin China
2. College of Life Sciences and Agriculture and Forestry Qiqihar University Qiqihar China
3. State Key Laboratory of New‐Tech for Chinese Medicine Pharmaceutical Process Jiangsu Kanion Pharmaceutical Co., Ltd. Lianyungang China
4. College of Chemistry and Chemical Engineering Qiqihar University Qiqihar China
Abstract
AbstractCannabidiol (CBD), the most abundant nonpsychoactive constituent of Cannabis sativa plant, is a promising potential pharmacotherapy for the treatment of diabetes and associated comorbidities. Previous studies have shown the potential of CBD to prevent diabetes in mice, the precise mechanisms of action remain unclear. The purpose of this study was to explore the mechanism of CBD alleviating hyperglycemia. The results demonstrated that CBD reduced blood glucose of STZ‐induced diabetic mice without causing hypoglycemia. To elucidate the possible mechanisms of CBD effect, RNA‐seq analysis was performed on high glucose‐induced human mesangial cells (HMCs). By cluster analysis of differential genes, the results showed that advanced glycation end products‐receptor of advanced glycation endproducts (AGE‐RAGE) pathway‐related genes CCL2 and interleukin‐1β (IL‐1β) play an important role in the biological of CBD. The expression of CCL2 and IL‐1β were significantly increased in HMCs. Whereas, treatment with CBD decreased the expression of CCL2 and IL‐1β. In addition, CBD significantly reduced AGE‐RAGE levels in high glucose‐induced HMCs. Similar results were confirmed in diabetic mice. In conclusion, we discovered for the first time that CBD ameliorates hyperglycemia partly through AGE‐RAGE mediated CCL2/IL‐1β pathway.